1. Home
  2. GRFS

as 08-15-2025 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Founded: 1940 Country:
Spain
Spain
Employees: N/A City: N/A
Market Cap: 7.2B IPO Year: 2006
Target Price: $10.30 AVG Volume (30 days): 1.3M
Analyst Decision: Hold Number of Analysts: 1
Dividend Yield:
1.32%
Dividend Payout Frequency: Annual
EPS: 0.53 EPS Growth: 132.60
52 Week Low/High: $6.19 - $11.14 Next Earning Date: 01-01-0001
Revenue: $8,744,226,659 Revenue Growth: 9.32%
Revenue Growth (this year): 5.4% Revenue Growth (next year): 6.74%

GRFS Daily Stock ML Predictions

Share on Social Networks: